PON1 and Alzheimer disease: Meta-analysis of the data published up to February 2023 (seven studies involving a total of 615 subjects, 281 AD patients, and 356 controls) showed that PON1 arylesterase activity, reflecting levels of the PON1 protein [87,88], was significantly reduced in AD patients compared with controls [89].